ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 119 filers reported holding ARBUTUS BIOPHARMA CORP in Q1 2022. The put-call ratio across all filers is 1.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $139 | +21.9% | 44,968 | +1.4% | 0.00% | – |
| Q1 2024 | $114 | +0.9% | 44,348 | -1.5% | 0.00% | – |
| Q4 2023 | $113 | +22.8% | 45,006 | -0.5% | 0.00% | – |
| Q3 2023 | $92 | -10.7% | 45,246 | +1.1% | 0.00% | – |
| Q2 2023 | $103 | -24.3% | 44,773 | -0.3% | 0.00% | – |
| Q1 2023 | $136 | -22.7% | 44,893 | -40.5% | 0.00% | – |
| Q4 2022 | $176 | -99.9% | 75,406 | -0.1% | 0.00% | – |
| Q3 2022 | $144,000 | -29.4% | 75,476 | +0.5% | 0.00% | – |
| Q2 2022 | $204,000 | +106.1% | 75,132 | +126.2% | 0.00% | – |
| Q1 2022 | $99,000 | -23.3% | 33,217 | +0.1% | 0.00% | – |
| Q4 2021 | $129,000 | -9.8% | 33,176 | -0.4% | 0.00% | – |
| Q3 2021 | $143,000 | -29.6% | 33,322 | -50.2% | 0.00% | – |
| Q2 2021 | $203,000 | +130.7% | 66,900 | +173.1% | 0.00% | – |
| Q1 2019 | $88,000 | -6.4% | 24,500 | 0.0% | 0.00% | – |
| Q4 2018 | $94,000 | -59.5% | 24,500 | 0.0% | 0.00% | – |
| Q3 2018 | $232,000 | +29.6% | 24,500 | 0.0% | 0.00% | – |
| Q2 2018 | $179,000 | – | 24,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,651,825 | $19,358,000 | 6.60% |
| RTW INVESTMENTS, LP | 5,165,499 | $37,708,000 | 2.72% |
| Eversept Partners, LP | 97,495 | $711,714 | 0.33% |
| Seelaus Asset Management LLC | 14,300 | $104,000 | 0.09% |
| LADENBURG THALMANN FINANCIAL SERVICES INC. | 1,765,315 | $8,827,000 | 0.08% |
| ALGERT GLOBAL LLC | 34,816 | $254,000 | 0.05% |
| BOOTHBAY FUND MANAGEMENT, LLC | 48,000 | $350,000 | 0.03% |
| OXFORD ASSET MANAGEMENT LLP | 211,115 | $1,540,000 | 0.03% |
| PRIMECAP MANAGEMENT CO/CA/ | 4,000,400 | $29,203,000 | 0.02% |
| PDT Partners, LLC | 66,965 | $489,000 | 0.02% |